Investor Presentation
|
|
- Carol Howard
- 5 years ago
- Views:
Transcription
1 Fr persnal use nly Investr Presentatin Dr. Marie Rskrw, CEO & Managing Directr September 2014 ASX: PAB
2 Fr persnal use nly Safe Harbur Statement This presentatin cntains frward-lking statements that are subject t risks and uncertainties. Such statements invlve knwn and unknwn risks that may cause the actual results, perfrmance r achievements f Patrys Limited t be materially different frm the statements in this presentatin. Actual results culd differ materially depending n factrs such as the availability f resurces, the results f clinical studies, the timing and effects f regulatry actins, the strength f cmpetitin and the effectiveness f the Cmpany's patent prtectin. 2
3 Fr persnal use nly Highlights f rd Quarter (July September): Released details f the planned PAT-SM6 & carfilzmib Phase Ib/IIa clinical trial due t start end f 2014 Reprted significant prgress n all preclinical prgrammes Prgressed the GMP manufacturing f PAT-SM6 2 nd Quarter (April June): Reprted the granting f a third US patent fr PAT-SM6 Released clinical data shwing that a patient with end-stage multiple myelma respnded psitively t treatment with PAT-SM6 in cmbinatin with ther marketed drugs Reprted the first plant-based prductin f PAT-SM6 1 st Quarter (January t March): Reprted final data frm successful Phase I/IIa PAT-SM6 single-agent clinical trial Rights issue cmpleted: Ttal fundraising f $7.7 millin PAT-SC1 10yr fllw-up clinical trial data in patients with gastric cancer published 3
4 Fr persnal use nly Vlume (m) Share Price A$ Crprate Overview KEY STATS & FINANCIALS 17 SEPT (AUD$) MANAGEMENT & BOARD ASX Cde PAB Share price $ week high $ week lw $0.021 Shares n issue 697,060,986 Market capitalisatin $14.6m 30/6/14 $8.6m Funding Since Listing $54m Marie Rskrw, BSc (Hns), MBBS, PhD Rger McPhersn, CPA, GAICD Frank Hensel, PhD Jhn Read, BSc (Hns), MBA, FAICD Mike Strk, BBA Suzy Jnes Managing Directr, CEO CFO, Cmpany Secretary Vice President R&D Nn-Executive Chairman Nn-Executive Directr Nn-Executive Directr CURRENT YEAR SHARE PERFORMANCE $0.061 $0.051 $0.041 $0.031 $0.021 $ Jan Jan Feb Mar Mar Apr May May Jun Jul Jul Aug 14 4
5 Fr persnal use nly Pipeline Prduct (Target) Discvery Preclinical Phase I Phase 2a PAT-SM6 (GRP78) Melanma Phase I Cmpleted PAT-SM6 (GRP78) Multiple Myelma Single Agent Phase I/IIa Cmpleted 2013 PAT-SM6 (GRP78) Multiple Myelma Cmbinatin Carfilzmib Phase Ib/IIa Cmmence 2014 PAT-LM1 (NONO) PAT-SC1 (CD55) PAT-SM3 PAT-SM4 PAT-H12 Slid Tumurs Gastric Cancer Phase I/IIa Cmpleted Out- Licensing Candidate 5
6 Fr persnal use nly PAT-SM6
7 Fr persnal use nly Patrys Lead Antibdy: PAT-SM6 PAT-SM6: IgM istype, λ-light chain Islated frm stmach cancer patient Targets tumur specific epitpe n GRP78 Binds als t xidised LDL and VLDL Mde f Actin: Internalisatin upn binding f xidised LDL & GRP78 PAT-SM6 Internalisatin triggers apptsis In viv & In vitr Reactivity: Effective in multiple xengraft mdels Expressin data shw specific expressin in wide range f tumurs incl. melanma and myelma 7
8 Fr persnal use nly Multiple Myelma - Opprtunity Multiple Myelma Opprtunity Cancer f the plasma cells in bne marrw. Cells grw ut f cntrl and frm tumurs in slid bne, cause damage t ther rgans Estimated t be mre than 220,000 cases wrldwide and incidence increasing 5 year survival f ~30% Market expected t increase frm $8B (2013) t >$15B (2018) Market currently dminated by 3 prducts: Revlimid (net sales $4.28B 2013) Velcade (net sales $3.77B 2013) Kyprlis (carfilzmib) (net sales $272M 2013) Several MAbs currently in clinical develpment but nne apprved t date. Likely t be used in cmbinatin therapies Significant interest in MM frm bth large pharmaceutical and bitechnlgy cmpanies 8
9 Fr persnal use nly Multiple Myelma Pathlgy Abnrmal plasma cells (myelma cells) secrete lts f useless antibdies (M prteins) Abnrmal prteins in serum detected by electrphresis Myelma cells crwd ut ther bld cells resulting in anaemia, thrmbcytpenia (bleeding) and leucpenia (infectins) Abnrmal prteins (Bence Jnes) detected in urine Myelma cells 9
10 Fr persnal use nly Multiple Myelma Clinical Presentatin Bne disease and hypercalcaemia Abnrmal prtein depsits Bne marrw failure and infectins 10
11 Fr persnal use nly Therapies fr Multiple Myelma Prtesme inhibitrs Brtezmib (Velcade) Carfilzmib (Kyprlis) Immunmdulatrs (IMIDs) Lanalidmide (Revlimid) Pmalyst (Pmalidmide) Thalidmide Stem cell transplantatin Autlgus Allgeneic Clinical studies Small mlecules Antibdies, peptides Immuntherapeutics Chemtherapeutics Melphalan Cisplatin Cyclphsphamide Dxrubicin 11
12 Fr persnal use nly Antibdies in Clinical Trials fr MM Daratumumab (Genmab/Janssen Bitech,Phase III) MOR 202 (MrphSys/Celgene, Phase I/IIa) PAT-SM6* (Patrys, Phase Ib/IIa) Eltuzumab (BSM/Abbtt, Phase III) GRP78 BHQ880 (Nvartis, Phase II) Antibdies in all stages f clinical develpment *Upcming trial t begin end f 2014 with PAT-SM6 in cmbinatin with carfilzmib and dexamethasne CD138 txin- cnjugated (BT062, Bitest AG, Phase I/IIa) 12
13 Fr persnal use nly PAT-SM6 Mntherapy Trial 12 patients treated with 4 dses PAT-SM6 in 4 dse chrts (0.3mg/kg, 1mg/kg, 3mg/kg and 6mg/kg/dse) evaluated at day +36 (end f trial) 10 male, 2 female: median age 71 yrs Received average 5 prir lines f therapy PAT-SM6 safe in all patients. N dse limiting txicity (DLT), n related serius adverse events (SAE) and n related adverse event grade 4 N evidence f immungenicity. PK analysis shwed half-life f 7 hrs PAT-SM6 specifically targets MM cells in viv and stimulates significant immune respnses 4/12 patients had stable disease (day +36 pst treatment) with a significant reductin in prtein M levels in the peripheral bld Patients wh received prir treatment with prteasme inhibitrs respnded best t PAT-SM6 Mean time t next therapy is 51 days (clinically significant). Tw patients had stable disease fr >130 days pst treatment 13
14 Fr persnal use nly Increase/Decrease Clinical Data Preliminary Efficacy M Prtein Changes frm Baseline (%) 140% 120% 114% 100% 80% Stable disease Stable disease Stable disease Stable disease 81% 60% 40% 42% 54% 36.30% 48% 40% 20% 0% -20% -40% 13% 7% 1.40% 1% % 0.3 mg/kg 1 mg/kg 3 mg/kg 6 mg/kg 4 patients shwed stable disease accrding t the IMWG criteria 14
15 Fr persnal use nly Clinical Data anti CD138 Istype Cntrl PAT-SM6 PAT-SM6 Istype Cntrl Immunhistchemical staining with PAT- SM6 n paraffin embedded tumur bipsies frm MM patients The psitive cntrl (anti-cd138) and PAT- SM6 bund t patient tissues PAT-SM6 Istype Cntrl Flw cytmetry n MM patient bne marrw Cells frm MM patients displayed cell surface binding fr PAT-SM6 suggestive the target (GRP78) is present n the MM cells anti-id CD138 merge Detectin f PAT-SM6 n circulating MM cells Befre and after dsing, patient bld was cllected and circulating MM cells were purified using CD138 magnetic beads. PAT-SM6 binding was cnfirmed using an anti-iditype antibdy specific fr PAT- SM6 (anti-id) by cnfcal micrscpy. In the psttreatment sample, red stained MM cells indicate the presence f PAT-SM6. CD138 was used as a psitive cntrl Pre-treatment Pst-treatment 15
16 Fr persnal use nly PAT-SM6 & Carfilzmib Cmbinatin Trial Endpints: 16 Primary: The safety and tlerability f PAT-SM6, given in cmbinatin with carfilzmib and dexamethasne in patients with multiple myelma wh are refractry and/r intlerant t brtezmib, a currently-marketed prteasme inhibitr Secndary: Overall respnse rate, duratin f respnse, time t prgressin and a series f wellestablished assays will measure immunlgical and disease parameters Design: Single-arm study with a 2-stage design: after treating 9 pts in the 1 st stage, if > 2 respnd (a partial respnse r better), the trial will cntinue t the 2nd stage and a ttal f 24 pts will be treated Each pt will be treated with up t 4 cycles f PAT-SM6 (6 mg/kg/dse) + carfilzmib (20-27 mg/m 2 ) + dexamethasne (40 mg) Each cycle will cnsist f 3 dses f PAT-SM6, 6 dses f carfilzmib and 4 dses f dexamethasne administered ver ne mnth Timelines: Trial prjected t start end f 2014 at 2 clinical centres in Germany (Würzburg & Dresden) Prgressive recruitment f up t 24 pts estimated t take mnths. Data frm first 9 patients will be released
17 Fr persnal use nly Cell Lines Used in Manufacturing Antibdies PER.C6 Cell Line: Patrys uses PER.C6 human cell line fr GMP prductin: Only human cell line cmmercially available Over 6300 patients have been treated with PER.C6 prducts safe prfile PER.C6 cell line has received regulatry apprval in all majr markets PER.C6 derived prducts have nt yet gained marketed apprval: Currently in Phase III Capable f prducing high yields f bth IgM and IgG antibdies. Cst f gds similar t CHO system Chinese Hamster Ovary (CHO) Cell Line: CHO is a cmmnly used cell nn-human cell line: CHO is mre familiar t big Pharma / Bitech cmpanies Numerus antibdy therapeutics prduced in CHO are n the market Patrys has initiated a feasibility study with CHO cells in rder t deliver multiple ptins t ptential partners 17
18 Fr persnal use nly PAT-LM1
19 Fr persnal use nly PAT-LM1 Antibdy & Target PAT-LM1: IgM istype, λ-light chain Islated frm a lung cancer patient Targets tumur-specific epitpe f surfaceexpressed NONO (nn-pou-dmain-cntaining ctmer binding prtein) Mde f Actin: NONO mainly fund in nucleus: invlved in transcriptinal & pst-transcriptinal gene regulatin Unknwn mechanism-f-transprt t cell membrane In Viv & In Vitr Reactivity: Effective in several xengraft mdels Expressin data shw specific expressin in a wide range f tumrs incl. lung, pancreas, cln, leukaemias Crystal structure f NONO with PSPC1 Passn et al PNAS
20 Tumur vlume mm 3 Fr persnal use nly OD655 PAT-LM1 Preclinical Data Lung Squamus Cell Carcinma + cntrl - cntrl PAT-LM withut C1q cating with 5μ/ml C1q cating 0.3 Cln Adencarcinma Esphagus Squamus Cell Carcinma Breast Ductal Adencarcinma μg 10μg 5μg 1μg 0.5μg IHC staining with PAT-LM1 n tumur tissues Lung cancer xengraft (n=10 per grup) Saline IgM PAT-LM1 20 A) Individual (symbls) and mean (bar) tumr vlume H&E (200µg) Appttic cells A) Individual (symbls) and mean (bar) tumr vlume Regressin PAT-LM1 binds C1q, suggestive f CDC Cytkeratin Cntrl Cntrl tumr (n=10 per tumr PAT-LM1 grup) LM-1 treated treated tumr tumr Cytkeratin Necrsis (200µg) B) Histlgy n excised tumurs H&E LM1 Cntrl Cntrl tumr tumr PAT-LM1 reduced tumur vlume & induced cell-death Appttic cells Regressin Necrsis PAT-LM1 LM-1 treate treate B) Histlgy n excised tumurs
21 Fr persnal use nly PAT-SC1
22 Fr persnal use nly PAT-SC1 (Gastric Cancer) PAT-SC1: 22 Pentameric IgM istype, λ-light chain Islated frm a stmach cancer patient Targets isfrm f CD55 (Decay Accelerating Factr) expressed n surface f multiple types f cancer cells POC Trial Results: Phase I/IIa (POC) pen-label trial cnducted (Germany) Safe in 51 pts receiving single 20 mg dse PAT-SC1 Significant 10 year survival benefit fr 30 pts with minimal residual disease (R0) pstsurgery vs. untreated pts (histric cntrl) Current Stage/Cmpetitin: Currently in ut-licensing prcess Cnversin frm hybridma t recmbinant PER.C6 cell line cmpleted Orphan designatin by the FDA fr use in gastric cancer N ther knw clinical prducts targeting CD55 Intellectual Prperty: Key patent granted in varius jurisdictins
23 Fr persnal use nly 2014 Key Milestnes Key Milestne Prjected Timing (CY) PAT-SM6: Final data frm mntherapy MM trial Cmplete GMP manufacturing fr cmbinatin MM trial Cmmence cmbinatin Phase Ib/IIa MM trial Preclinical and clinical data published 1Q, H, Q, Q, 2014 PAT-LM1: Cmplete manufacturing prcess develpment ready fr scale-up Preclinical data published PAT-SC1: Preclinical & clinical trial (gastric cancer) data published Out-licensing deal 2H, H, Q, Discvery Abs: Target wrk n PAT-SM3, PAT-SM4, PAT-H
24 Fr persnal use nly Fr Further Infrmatin Cntact Details: Dr. Marie Rskrw, Chief Executive Officer / Managing Directr Mr. Rger McPhersn, Chief Financial Officer Ph: inf@patrys.cm Website:
Patrys To Present at the 12 th Annual BIO Investor Forum
ASX & Media Release Patrys T Present at the 12 th Annual BIO Investr Frum Melburne, Australia; 9 Octber, 2013: Patrys Limited (ASX: PAB), a clinical stage bitechnlgy cmpany tday annunced that Dr. Marie
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationREPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE
REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS
More informationPress Release. Adocia: Activity and results for the first half of 2013
Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result
More informationINTERIM REPORT JANUARY SEPTEMBER 2017
INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap):
More informationMEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?
MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins
More informationPress Release. Adocia Reports Operational and Financial Results for the First Half of 2014
Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationAugust November 2018
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer 3Q 2018 Reprt August 2018 1 Nvember 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More informationAction plan: serialisation of Nordic packages focus on Product Codes
19.6.2017, versin 5 Actin plan: serialisatin f Nrdic packages fcus n Prduct Cdes The aim f this dcument is t help pharma cmpanies t prepare fr prduct cde changes and t be able t maintain prduct cdes in
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationName: Date: Period: Notes: The Blood and Lymphatic System
Name: Date: Perid: Cmpsitin f Bld and their Functins Red Bld Cells (aka ) Structure Ntes: The Bld and Lymphatic System D nt have a like ther cells d Cntain a specialized prtein called Hemglbin cntains
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationProtocol Abstract and Schema
NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD-0332991 (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationUpdates to Medical Policies and Clinical UM Guidelines
Updates t Medical Plicies and Clinical UM Guidelines Effective May 1, 2016 The majr new plicies and changes are summarized belw. Please refer t the specific plicy fr cding, language, and ratinale updates
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationINTRODUCTION TO THE CIRCULATORY SYSTEM
INTRODUCTION TO THE CIRCULATORY SYSTEM What des bld d? 5. What makes this pssible? : In rder fr there t be an efficient exchange f xygen, waste and nutrients there must be a high surface area between the
More informationImportant NOTICE AND DISCLAIMER
1 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements based n uncertainty, since they relate t events and depend n circumstances that will ccur in future and which, by their
More informationActivating the patient s immune system to fight. system to. Company presentation. fight cancer. 4Q and Full Year August 14 February
Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin 4Q and Full Year 2018 fight cancer August 14 February 2019 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains
More information1.6. Topic 1: Cell Biology (Teacher) Essential Idea: Cell division is essential but must be controlled. 1.6 Cell Division
Tpic 1: Cell Bilgy (Teacher) 1.6 Essential Idea: Cell divisin is essential but must be cntrlled. 1.6 Cell Divisin Why d cells divide: - Sa:Vl Rati - Allws fr grwth f the rganism - Allws fr cell differentiatin
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationHealth Science Ch. 16 Cancer Lecture Outline
Cancer Leading cause f disease-related death amng peple under age 75 Secnd leading cause f death Evidence supprts that mst cancers culd be prevented by simple lifestyle changes Tbacc is respnsible fr abut
More informationInvestor Presentation
Investr Presentatin May 2018 nclyticsbitech.cm TSX ONC OTCQX ONCYF Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s business prspects and the develpment
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationSCALES NW HEARING PROTECTION PROGRAM
PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationACMPR - Access to Cannabis for Medical Purposes Regulations Part 1 Commercial Production
- Access t Cannabis fr Medical Purpses Regulatins Part 1 Cmmercial Prductin September 2017 OVERVIEW Yu must cmply with regulatins t supply medical cannabis as f August 24, 2016 There are fur parts t the
More informationARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST
ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST 7 th July 2017 Cntent 1 Intrductin 2 Tpics fr EOI in the 4 th call 3 The applicatin prcess and imprtant dates 4 Guideline fr EOIs Deadline
More informationWhere do we stand today?
Where d we stand tday? Nte by the United Natins Secretary-General transmitting the reprt f the Directr-General f WHO n the preventin and cntrl f NCDs (10 December 2013) Paragraph 43. Remarkable prgress
More informationNonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer
Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,
More informationActivating the immune system to fight cancer. ABG Sundal Collier Oslo 12 June 2018
Activating the immune system t fight cancer ABG Sundal Cllier Osl 12 June 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain frward-lking statements based n uncertainty, since they relate t
More informationVITAPRO. Detoxification properties of Apple pectin formulation, PROPECTIN. CENTRE D ETUDE ET DE VALORISATION DES ALGUES FINAL REPORT.
CENTRE D ETUDE & DE VALORISATION DES ALGUES 2400 Detxificatin prperties f Apple pectin frmulatin, PROPECTIN. VITAPRO FINAL REPORT PrPectin July 2015 CENTRE D ETUDE ET DE VALORISATION DES ALGUES PRESQU
More informationPancreatic Cancer Treatment Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The rising prevalence f besity, alchl cnsumptin, and smking is expected t prpel
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationInvestor Presentation
Investr Presentatin August 2018 nclyticsbitech.cm Nasdaq ONCY TSX ONC Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s business prspects and the
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationThe Cannabis Act and Regulations
The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics
More informationConsensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline
Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationFinding the right 90 people in 90 days and what to do with them:
Finding the right 90 peple in 90 days and what t d with them: Wh can yu give the 3 packets (with instructins) t? Current Preferred Custmers nt currently n the Daily Essentials Packets. Friends and Family
More informationAP Biology Immune System. Pathogens: agents that cause disease Immunity: the ability to avoid disease when invaded by a pathogen
AP Bilgy Pathgens: agents that cause disease Immunity: the ability t avid disease when invaded by a pathgen Innate Immunity: nnspecific First line f defense Barriers such as skin Hard fr bacteria t penetrate
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationNPCR CLINICAL EDIT CHECKS
NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t
More informationCONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW
FACT SHEET CONTACT: Amber Hamiltn 212-266-0062 TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW Type 2 diabetes accunts fr 90-95% f the 29.1 millin diabetes cases in the U.S. 1 Obesity is a majr independent
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationThe Cell Cycle & Cellular Division
The Cell Cycle & Cellular Divisin Name: Perid: Date: I. Cell Divisin: All are derived frm preexisting cells (Cell Thery) is the prcess by which cells prduce new cells Cells grw in number, NOT in Smaller
More informationHPV VACCINATION IN SANDYFORD SERVICES
HPV VACCINATION IN SANDYFORD SERVICES 1. General infrmatin n HPV Vaccinatin 2. HPV vaccinatin in females 3. Yung Wmen Only 4. HPV vaccinatin in MSM 1. General infrmatin General Infrmatin fr clinicians
More informationProgramme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport
Prgramme f Learning Physical Educatin Key Stage 4 Year 10 BTEC Sprt BTEC Sprt Level 2 Unit 1Fitness fr Sprt and Exercise... 2 Learning aim A: Knw abut the cmpnents f fitness and the principles f training...
More informationInvestor Update November 2011
Investr Update Nvember 2011 Cmpany Strategy Prject Style Cnventinal High Impact Prjects (ie big prspects: high IP s and large well reserves). Strng 3D prspects with gd analgues prspects are selected based
More informationSubject: Venetoclax (Venclexta ) Tablet
09-J2000-64 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 01/15/19 Subject: Venetclax (Venclexta ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationBelgian Volition SA - a VolitionRx Company- Technological company presentation BIOWIN DAY 2014
Belgian Vlitin SA - a VlitinRx Cmpany- Technlgical cmpany presentatin BIOWIN DAY 2014 Abut VlitinRx Wh we are Lab and Head ffice in Namur, Belgium Creatin: Oct 2010 8 emplyees + Internatinal Bard f Directrs
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationIndirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version
Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationSmoking Cessation Improvement in SFHN Primary Care,
Smking Cessatin Imprvement in SFHN Primary Care, 2015-16 David Silven, PhD, Supervising Psychlgist, SFHN Primary Care Behaviral Health Ellen Chen, MD, Directr f Quality, SFHN Primary Care Why smking assessment
More informationActelion Presents REPAIR Study Interim Analysis at the American College of Cardiology's 68th Annual Scientific Session
Interim Analysis Shwed Treatment with OPSUMIT (macitentan) Assciated with Significant Imprvement in Right Ventricular (RV) Functin and Pulmnary Vascular Resistance (PVR) in Patients with Pulmnary Arterial
More informationActivating the immune system to fight cancer
Activating the immune system t fight cancer RedEye pre-asco seminar Erik Digman Wiklund, CFO 28 May 2018 Frm a sequential treatment strategy directly targeting the cancer 1 Surgery When pssible, surgical
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationS.K.J Construction Ltd Groundwork & Civil Engineering
S.K.J Cnstructin Ltd Grundwrk & Civil Engineering SUBSTANCE MISUSE POLICY 1 2 SUBSTANCE MISUSE POLICY 1 INTRODUCTION Plicy Aims Frm the viewpint f health and safety at wrk, SKJ Cnstructin Ltd (the Cmpany)
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationChimeric Antigen Receptor T cell Therapy (CAR-T)
Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable
More informationTeam Seek and Destroy
Team Seek and Destry 3 Ideas Presentatin March 14, 2012 Marianne Lintz David McClelland Gabi Garcia Jenn Thrntn Hannah Kemptn Mentrs: Nahum and Lauren Diabetes http://www.healthaidindia.cm/diabetes-care-in-india/mnitring-bld-sugar-level.html
More informationHumanities and Social Sciences Division. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: SIGN 108 Fingerspelling Humanities and Scial Sciences Divisin Sign
More informationCancer of Unknown Primary (CUP) Pathways and Guidelines (v 2) London Cancer. April 2017
Cancer f Unknwn Primary (CUP) Pathways and Guidelines (v 2) Lndn Cancer April 2017 The fllwing pathways and guidelines dcument has been cmpiled by the Lndn Cancer CUP technical subgrup and agreed by the
More informationCHEMOPREVENTION in BREAST CANCER
CHEMOPREVENTION in BREAST CANCER Ozlem Er, M.D. Assc Prf f Medical Onclgy ESMO Curse Essentials f Medical Onclgy Outline Risk Assessment Mlecular Targets ER psitive Breast Cancer Tamxifen Ralxifene Lasfxifene
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationb. Responses/Reflexes Food bulk stretches the fundus of stomach, activating mechanoreceptors GI peptides activate chemoreceptor s o o o
QUIZ/TEST REVIEW NOTES SECTION 2 GASTRIC PHASE OF DIGESTION DIGESTIVE SYSTEM CHAPTER 21 I. ENTERIC NERVOUS SYSTEM a. Defined and Crrelatin with Shrt Reflexes Fund in walls f LUMEN Invlved in shrt reflexes
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationThe research question: What was discovered in the 1940s that could treat syphilis?
Psychlgy B30 Human Sexuality Sexually Transmitted Infectins Tuskegee Syphilis Experiment Ppulatin: The research questin: What was discvered in the 1940s that culd treat syphilis? Hw many men died f syphilis
More informationNATIONAL SENIOR CERTIFICATE GRADE 12
NATIONAL SENIOR CERTIFICATE GRADE 12 INFORMATION TECHNOLOGY P1 FEBRUARY/MARCH 2015 MARKS: 150 TIME: 3 hurs This questin paper cnsists f 19 pages. Infrmatin Technlgy/P1 2 DBE/Feb. Mar. 2015 INSTRUCTIONS
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More information